Acute management of patients presenting with neurological symptoms while on an anti-TNF agent typically follows the treatment recommendations for acute exacerbations of multiple sclerosis, including intravenous (IV) or oral corticosteroids, with good results in the short term, although the long-term course of the demyelinating disease appears unpredictable [38, 39]. The gene discussed is TNF; the disease is multiple sclerosis.